Potential Eylea side effects from the manufacturer Regeneron Pharmaceuticals, Inc.
"...IMPORTANT SAFETY INFORMATION FOR EYLEA® (aflibercept) INJECTION
EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Intravitreal injections, including those with EYLEA, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering EYLEA. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately. Intraocular inflammation has been reported during the post approval use of EYLEA.
Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
There is a potential risk of arterial thromboembolic events (ATEs) following use of intravitreal VEGF inhibitors, including EYLEA, defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of ATEs in the VIEW 1 and VIEW 2 wet AMD studies in patients treated with EYLEA was 1.8% during the first year. The incidence of ATEs in the COPERNICUS and GALILEO CRVO studies was 0% in patients treated with EYLEA compared with 1.4% in patients receiving sham control during the first six months.
The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and increased intraocular pressure.
Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with EYLEA including endophthalmitis, traumatic cataract, increased intraocular pressure, and vitreous detachment...."
Potential Lucentis side effects from the manufacturer Genentech USA, Inc.
"...What important safety information should I know about LUCENTIS?
LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. LUCENTIS is not for everyone. You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients.
Some LUCENTIS patients have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. Other uncommon serious side effects include inflammation inside the eye and increased eye pressure. These side effects can make your vision worse. Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health during the week after your LUCENTIS injection.
Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes.
If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away.
The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non–eye-related side effects are nose and throat infections, headache, lung/airway infections, and nausea.
"...The production of the functional polypeptides is expensive and technical problems related to physical properties and purity are frequently encountered. Gene transfer represents an alternative method to deliver angiostatin. Gene therapy has the potential to produce the therapeutic agent in high concentrations in a local area for a sustained period, thereby avoiding the problems encountered with long-term administration of recombinant proteins, monoclonal antibodies, or anti-angiogenic drugs...."
You reiterated "Endostatin replacement therapy may prevent neovascularization in the retina, and it has virtually no side effects..." look up the definition of the word "virtually"
Yes, there have been reports of short term (about one month or less) inflammation after immediately following treatment with RetinStat. That is virtually no side effects. The inflamation is a short term transient side effect and easily treated.
Compare that to the side effects of the current treatments
I agree endostatin and angiostatin should be safe, however they are not normally expressed in the eye so there can always be unintended side effects, so no drug can ever be assumed to be totally safe, especially when so few people have ever been treated with them. Even your own quote shows that it has virtually no side effects which is not no side effects - "Endostatin replacement therapy may prevent neovascularization in the retina, and it has virtually no side effects..."
As for OXB working on them as an oncology product, a quick check of their pipeline shows that has been shelved.
What is your evidence for the synergy effect of the two working together?
Lastly Angiostatin might be expensive to produce in the laboratory but not for a manufacturer, in fact based on a quick search it is in fact relatively easy to produce at large scale and low cost. http://www.ncbi.nlm.nih.gov/pubmed/11049746 So why are no big pharma/biotechs doing this, even the company who was leading clinical trials in USA handed the product back to the boston childrens hospital.
hi guys ive been in this share for only a couple of weeks only put 600 pound in which is significantly more now this is the best share so far tha t im in judging by th elovely little ticks up everyday and not one red day since ive been wish they were all like this i think looking at the charts over the last two to three years and with the recent dea with noventis that this share is going through a rerating now by the looks of it asits moving up quite and on little volume thahs just my thoughts
I have never ever mentioned another share on another board and it boils my **** when I see people doing it. However, you guys here obvioulsy know your science. I have been watching OXB for over a year and it has disapointed, maybe it will have its day and I will leave a token 1k investment just incase. However, check out IMM, phase 3 drug development, potential multibagger, even at 25% discout rate they value at over 200p. I accept some negative remarks regarrding this post that is fair enough, I would probably do the same, but it literally takes 5 minutes of your day if that. God bless George and god bless America
We do not need to extrapolate Endostatin and AngioStatin are two of the most potent angiognesis inhibitors known to man. This is a known fact to any researcher in the field of ant-angiogenesis.
There is no doubt that Endostatin and Angiostatin are synergistic. In fact it is estimated that the combination of Endostatin and Angiostatin could be up to 20 times more potent than either Endostatin aor Angiostatin alone.
You are partially correct that until RetinoStat Endostatin and Angiostatin have never been tried in combination in humans.
Endostatin has been used to treat hundreds of human patients. Can you name one case where endostatin treatment has caused even one serious adverse side effect in a human?
Angiostatin is very difficult and expensive to produce in the laboratory and human trials have been limitted to under one hundred people. Can you name even one aderse side effect reported in any human due to Angiostatin.
Both Endostatin and Angiostatin are safe because they are naturally found in every human and every mammal.
"...Endostatin, actually, is an interesting example of evolution. It is very old, at least 600 million years old. It is found in animals beginning from early worms onward, and its amino acids have been faithfully copied all these years. In primitive animals it was only used to guide nerve growth, but in more complex animals it is also used to guide vessel growth...."
"...1994 Lab discovered angiostatin, the first angiogenesis inhibitor found inside another protein...."
"...1997 Lab discovered endostatin, another angiogenesis inhibitor found inside a protein..."
"...How did angiogenesis inhibitors come to benefit eye medicine?
The capacity to reverse vascularization was an obvious boost to ophthalmology all along. But more than that, Evangelos Gragoudas, Joan Miller, Björn Olsen and colleagues have recently discovered that neovascular macular degeneration can actually be considered analogous to a deficiency disease of endostatin.3 Endostatin normally suppresses VEGF receptors. So they made a neovascular model in mice and successfully gave endostatin as replacement therapy. Endostatin replacement therapy may prevent neovascularization in the retina, and it has virtually no side effects..."
Read about endostatin from an interview at the American Adademy of Ophthalmology
Not Hans, but here is my response to your postings.
Firstly Endostatin and Angiostatin look good in anecdotal evidence as possible potent oncology drugs, this could be a potential secondary market for RetinoStat, like the Lucentis/Avastin story
So by extrapolation they could be potent anti-angiogenesis therapies and that is what the current trial is designed to show.
However there is no evidence of them working in synergy, or being used in combination, so there could be unforeseen effects, because they are being expressed together more or less of them may be needed in a clinical environment with real patients as opposed to animal models, which can and do react differently.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.